-
1
-
-
33751099034
-
RNAi therapeutics: a potential new class of pharmaceutical drugs
-
1 Bumcrot, D., Manoharan, M., Koteliansky, V., Sah, D.W., RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2 (2006), 711–719.
-
(2006)
Nat. Chem. Biol.
, vol.2
, pp. 711-719
-
-
Bumcrot, D.1
Manoharan, M.2
Koteliansky, V.3
Sah, D.W.4
-
2
-
-
77957820261
-
RNAi and small interfering RNAs in human disease therapeutic applications
-
2 Lares, M.R., Rossi, J.J., Ouellet, D.L., RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 28 (2010), 570–579.
-
(2010)
Trends Biotechnol.
, vol.28
, pp. 570-579
-
-
Lares, M.R.1
Rossi, J.J.2
Ouellet, D.L.3
-
3
-
-
84883118140
-
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
-
3 Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P.N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369 (2013), 819–829.
-
(2013)
N. Engl. J. Med.
, vol.369
, pp. 819-829
-
-
Coelho, T.1
Adams, D.2
Silva, A.3
Lozeron, P.4
Hawkins, P.N.5
Mant, T.6
Perez, J.7
Chiesa, J.8
Warrington, S.9
Tranter, E.10
-
4
-
-
84914118074
-
Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials
-
4 Suanprasert, N., Berk, J.L., Benson, M.D., Dyck, P.J., Klein, C.J., Gollob, J.A., Bettencourt, B.R., Karsten, V., Dyck, P.J., Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. J. Neurol. Sci. 344 (2014), 121–128.
-
(2014)
J. Neurol. Sci.
, vol.344
, pp. 121-128
-
-
Suanprasert, N.1
Berk, J.L.2
Benson, M.D.3
Dyck, P.J.4
Klein, C.J.5
Gollob, J.A.6
Bettencourt, B.R.7
Karsten, V.8
Dyck, P.J.9
-
5
-
-
84904901858
-
Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection
-
5 Solano, E.C., Kornbrust, D.J., Beaudry, A., Foy, J.W., Schneider, D.J., Thompson, J.D., Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 24 (2014), 258–266.
-
(2014)
Nucleic Acid Ther.
, vol.24
, pp. 258-266
-
-
Solano, E.C.1
Kornbrust, D.J.2
Beaudry, A.3
Foy, J.W.4
Schneider, D.J.5
Thompson, J.D.6
-
6
-
-
84862173320
-
Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease
-
6 Lee, D.U., Huang, W., Rittenhouse, K.D., Jessen, B., Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease. J. Ocul. Pharmacol. Ther. 28 (2012), 222–230.
-
(2012)
J. Ocul. Pharmacol. Ther.
, vol.28
, pp. 222-230
-
-
Lee, D.U.1
Huang, W.2
Rittenhouse, K.D.3
Jessen, B.4
-
7
-
-
84892741671
-
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
-
7 Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B.R., Sutherland, J.E., Hutabarat, R.M., Clausen, V.A., Karsten, V., Cehelsky, J., et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383 (2014), 60–68.
-
(2014)
Lancet
, vol.383
, pp. 60-68
-
-
Fitzgerald, K.1
Frank-Kamenetsky, M.2
Shulga-Morskaya, S.3
Liebow, A.4
Bettencourt, B.R.5
Sutherland, J.E.6
Hutabarat, R.M.7
Clausen, V.A.8
Karsten, V.9
Cehelsky, J.10
-
8
-
-
84877120847
-
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement
-
8 Tabernero, J., Shapiro, G.I., LoRusso, P.M., Cervantes, A., Schwartz, G.K., Weiss, G.J., Paz-Ares, L., Cho, D.C., Infante, J.R., Alsina, M., et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3 (2013), 406–417.
-
(2013)
Cancer Discov.
, vol.3
, pp. 406-417
-
-
Tabernero, J.1
Shapiro, G.I.2
LoRusso, P.M.3
Cervantes, A.4
Schwartz, G.K.5
Weiss, G.J.6
Paz-Ares, L.7
Cho, D.C.8
Infante, J.R.9
Alsina, M.10
-
9
-
-
77951132901
-
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
-
9 Davis, M.E., Zuckerman, J.E., Choi, C.H., Seligson, D., Tolcher, A., Alabi, C.A., Yen, Y., Heidel, J.D., Ribas, A., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464 (2010), 1067–1070.
-
(2010)
Nature
, vol.464
, pp. 1067-1070
-
-
Davis, M.E.1
Zuckerman, J.E.2
Choi, C.H.3
Seligson, D.4
Tolcher, A.5
Alabi, C.A.6
Yen, Y.7
Heidel, J.D.8
Ribas, A.9
-
10
-
-
77952680862
-
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
-
10 Geisbert, T.W., Lee, A.C., Robbins, M., Geisbert, J.B., Honko, A.N., Sood, V., Johnson, J.C., de Jong, S., Tavakoli, I., Judge, A., et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375 (2010), 1896–1905.
-
(2010)
Lancet
, vol.375
, pp. 1896-1905
-
-
Geisbert, T.W.1
Lee, A.C.2
Robbins, M.3
Geisbert, J.B.4
Honko, A.N.5
Sood, V.6
Johnson, J.C.7
de Jong, S.8
Tavakoli, I.9
Judge, A.10
-
11
-
-
84877026189
-
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection
-
11 Wooddell, C.I., Rozema, D.B., Hossbach, M., John, M., Hamilton, H.L., Chu, Q., Hegge, J.O., Klein, J.J., Wakefield, D.H., Oropeza, C.E., et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 21 (2013), 973–985.
-
(2013)
Mol. Ther.
, vol.21
, pp. 973-985
-
-
Wooddell, C.I.1
Rozema, D.B.2
Hossbach, M.3
John, M.4
Hamilton, H.L.5
Chu, Q.6
Hegge, J.O.7
Klein, J.J.8
Wakefield, D.H.9
Oropeza, C.E.10
-
12
-
-
85013774429
-
4LBA A phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis
-
196–196
-
12 Beg, M., Brenner, A., Sachdev, J., Borad, M., Cortes, J., Tibes, R., et al. 4LBA A phase 1 study of first-in-class microRNA-34 mimic, MRX34, in patients with hepatocellular carcinoma or advanced cancer with liver metastasis. Eur. J. Cancer, 50, 2014 196–196.
-
(2014)
Eur. J. Cancer
, vol.50
-
-
Beg, M.1
Brenner, A.2
Sachdev, J.3
Borad, M.4
Cortes, J.5
Tibes, R.6
-
13
-
-
84885065624
-
First microRNA mimic enters clinic
-
13 Bouchie, A., First microRNA mimic enters clinic. Nat. Biotechnol., 31, 2013, 577.
-
(2013)
Nat. Biotechnol.
, vol.31
, pp. 577
-
-
Bouchie, A.1
-
14
-
-
85176869775
-
-
Mirna. (2016). Mirna Therapeutics Halts Phase 1 Clinical Study of MRX34.
-
14 Mirna. (2016). Mirna Therapeutics Halts Phase 1 Clinical Study of MRX34. http://files.shareholder.com/downloads/AMDA-2PXH94/3644053911x0x908896/E5BD13E6-BF9E-4FA3-9651-B51597F7FC90/MIRN_News_2016_9_20_General_Releases.pdf.
-
-
-
-
15
-
-
84960852206
-
Drug developers refocus efforts on RAS
-
15 Sheridan, C., Drug developers refocus efforts on RAS. Nat. Biotechnol. 34 (2016), 217–218.
-
(2016)
Nat. Biotechnol.
, vol.34
, pp. 217-218
-
-
Sheridan, C.1
-
16
-
-
80052468423
-
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
-
16 Saad, F., Hotte, S., North, S., Eigl, B., Chi, K., Czaykowski, P., Wood, L., Pollak, M., Berry, S., Lattouf, J.B., et al., Canadian Uro-Oncology Group. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin. Cancer Res. 17 (2011), 5765–5773.
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 5765-5773
-
-
Saad, F.1
Hotte, S.2
North, S.3
Eigl, B.4
Chi, K.5
Czaykowski, P.6
Wood, L.7
Pollak, M.8
Berry, S.9
Lattouf, J.B.10
-
17
-
-
84976444883
-
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides
-
17 Ackermann, E.J., Guo, S., Benson, M.D., Booten, S., Freier, S., Hughes, S.G., Kim, T.W., Jesse Kwoh, T., Matson, J., Norris, D., et al. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides. Amyloid 23 (2016), 148–157.
-
(2016)
Amyloid
, vol.23
, pp. 148-157
-
-
Ackermann, E.J.1
Guo, S.2
Benson, M.D.3
Booten, S.4
Freier, S.5
Hughes, S.G.6
Kim, T.W.7
Jesse Kwoh, T.8
Matson, J.9
Norris, D.10
-
18
-
-
84925064199
-
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease
-
18 Monteleone, G., Neurath, M.F., Ardizzone, S., Di Sabatino, A., Fantini, M.C., Castiglione, F., Scribano, M.L., Armuzzi, A., Caprioli, F., Sturniolo, G.C., et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N. Engl. J. Med. 372 (2015), 1104–1113.
-
(2015)
N. Engl. J. Med.
, vol.372
, pp. 1104-1113
-
-
Monteleone, G.1
Neurath, M.F.2
Ardizzone, S.3
Di Sabatino, A.4
Fantini, M.C.5
Castiglione, F.6
Scribano, M.L.7
Armuzzi, A.8
Caprioli, F.9
Sturniolo, G.C.10
-
19
-
-
84958680040
-
Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
-
19 Monteleone, G., Di Sabatino, A., Ardizzone, S., Pallone, F., Usiskin, K., Zhan, X., Rossiter, G., Neurath, M.F., Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease. Aliment. Pharmacol. Ther. 43 (2016), 717–724.
-
(2016)
Aliment. Pharmacol. Ther.
, vol.43
, pp. 717-724
-
-
Monteleone, G.1
Di Sabatino, A.2
Ardizzone, S.3
Pallone, F.4
Usiskin, K.5
Zhan, X.6
Rossiter, G.7
Neurath, M.F.8
-
20
-
-
77949485460
-
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
-
20 Raal, F.J., Santos, R.D., Blom, D.J., Marais, A.D., Charng, M.J., Cromwell, W.C., Lachmann, R.H., Gaudet, D., Tan, J.L., Chasan-Taber, S., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375 (2010), 998–1006.
-
(2010)
Lancet
, vol.375
, pp. 998-1006
-
-
Raal, F.J.1
Santos, R.D.2
Blom, D.J.3
Marais, A.D.4
Charng, M.J.5
Cromwell, W.C.6
Lachmann, R.H.7
Gaudet, D.8
Tan, J.L.9
Chasan-Taber, S.10
-
21
-
-
84868518061
-
Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease
-
21 Stein, E.A., Dufour, R., Gagne, C., Gaudet, D., East, C., Donovan, J.M., Chin, W., Tribble, D.L., McGowan, M., Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126 (2012), 2283–2292.
-
(2012)
Circulation
, vol.126
, pp. 2283-2292
-
-
Stein, E.A.1
Dufour, R.2
Gagne, C.3
Gaudet, D.4
East, C.5
Donovan, J.M.6
Chin, W.7
Tribble, D.L.8
McGowan, M.9
-
22
-
-
84995752459
-
Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line
-
22 Dowling, J.J., Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line. Nat. Rev. Neurol. 12 (2016), 675–676.
-
(2016)
Nat. Rev. Neurol.
, vol.12
, pp. 675-676
-
-
Dowling, J.J.1
-
23
-
-
85176855127
-
-
Editorial (2016). Railroading at the FDA. Nat Biotechnol. 34, 1078.
-
23 Editorial (2016). Railroading at the FDA. Nat Biotechnol. 34, 1078.
-
-
-
-
24
-
-
0025043480
-
The asialoglycoprotein receptor: a model for endocytic transport receptors
-
24 Spiess, M., The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry 29 (1990), 10009–10018.
-
(1990)
Biochemistry
, vol.29
, pp. 10009-10018
-
-
Spiess, M.1
-
25
-
-
0019130107
-
Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte
-
25 Schwartz, A.L., Rup, D., Lodish, H.F., Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte. J. Biol. Chem. 255 (1980), 9033–9036.
-
(1980)
J. Biol. Chem.
, vol.255
, pp. 9033-9036
-
-
Schwartz, A.L.1
Rup, D.2
Lodish, H.F.3
-
26
-
-
0028998769
-
The asialoglycoprotein receptor: relationships between structure, function, and expression
-
26 Stockert, R.J., The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev. 75 (1995), 591–609.
-
(1995)
Physiol. Rev.
, vol.75
, pp. 591-609
-
-
Stockert, R.J.1
-
27
-
-
34548267667
-
Endocytic mechanisms for targeted drug delivery
-
27 Bareford, L.M., Swaan, P.W., Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59 (2007), 748–758.
-
(2007)
Adv. Drug Deliv. Rev.
, vol.59
, pp. 748-758
-
-
Bareford, L.M.1
Swaan, P.W.2
-
28
-
-
63649163810
-
The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid alpha2,6-galactose
-
28 Steirer, L.M., Park, E.I., Townsend, R.R., Baenziger, J.U., The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid alpha2,6-galactose. J. Biol. Chem. 284 (2009), 3777–3783.
-
(2009)
J. Biol. Chem.
, vol.284
, pp. 3777-3783
-
-
Steirer, L.M.1
Park, E.I.2
Townsend, R.R.3
Baenziger, J.U.4
-
29
-
-
0027293871
-
Ca2+-dependent carbohydrate-recognition domains in animal proteins
-
29 Drickamer, K., Ca2+-dependent carbohydrate-recognition domains in animal proteins. Curr. Opin. Struct. Biol. 3 (1993), 393–400.
-
(1993)
Curr. Opin. Struct. Biol.
, vol.3
, pp. 393-400
-
-
Drickamer, K.1
-
30
-
-
0034697981
-
Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor
-
30 Meier, M., Bider, M.D., Malashkevich, V.N., Spiess, M., Burkhard, P., Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J. Mol. Biol. 300 (2000), 857–865.
-
(2000)
J. Mol. Biol.
, vol.300
, pp. 857-865
-
-
Meier, M.1
Bider, M.D.2
Malashkevich, V.N.3
Spiess, M.4
Burkhard, P.5
-
31
-
-
0019992236
-
Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line
-
31 Schwartz, A.L., Fridovich, S.E., Lodish, H.F., Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line. J. Biol. Chem. 257 (1982), 4230–4237.
-
(1982)
J. Biol. Chem.
, vol.257
, pp. 4230-4237
-
-
Schwartz, A.L.1
Fridovich, S.E.2
Lodish, H.F.3
-
32
-
-
0016322758
-
The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins
-
32 Ashwell, G., Morell, A.G., The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv. Enzymol. Relat. Areas Mol. Biol. 41 (1974), 99–128.
-
(1974)
Adv. Enzymol. Relat. Areas Mol. Biol.
, vol.41
, pp. 99-128
-
-
Ashwell, G.1
Morell, A.G.2
-
33
-
-
0017622966
-
Uptake and degradation of 125I-labelled asialo-fetuin by isolated rat hepatocytes
-
33 Tolleshaug, H., Berg, T., Nilsson, M., Norum, K.R., Uptake and degradation of 125I-labelled asialo-fetuin by isolated rat hepatocytes. Biochim. Biophys. Acta 499 (1977), 73–84.
-
(1977)
Biochim. Biophys. Acta
, vol.499
, pp. 73-84
-
-
Tolleshaug, H.1
Berg, T.2
Nilsson, M.3
Norum, K.R.4
-
34
-
-
0018746767
-
Coated pits, coated vesicles, and receptor-mediated endocytosis
-
34 Goldstein, J.L., Anderson, R.G., Brown, M.S., Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature 279 (1979), 679–685.
-
(1979)
Nature
, vol.279
, pp. 679-685
-
-
Goldstein, J.L.1
Anderson, R.G.2
Brown, M.S.3
-
35
-
-
0018362478
-
The binding site of rabbit hepatic lectin
-
35 Sarkar, M., Liao, J., Kabat, E.A., Tanabe, T., Ashwell, G., The binding site of rabbit hepatic lectin. J. Biol. Chem. 254 (1979), 3170–3174.
-
(1979)
J. Biol. Chem.
, vol.254
, pp. 3170-3174
-
-
Sarkar, M.1
Liao, J.2
Kabat, E.A.3
Tanabe, T.4
Ashwell, G.5
-
36
-
-
0018366405
-
Intracellular localization and degradation of asialofetuin in isolated rat hepatocytes
-
36 Tolleshaug, H., Berg, T., Frölich, W., Norum, K.R., Intracellular localization and degradation of asialofetuin in isolated rat hepatocytes. Biochim. Biophys. Acta 585 (1979), 71–84.
-
(1979)
Biochim. Biophys. Acta
, vol.585
, pp. 71-84
-
-
Tolleshaug, H.1
Berg, T.2
Frölich, W.3
Norum, K.R.4
-
37
-
-
0019159338
-
Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes
-
37 Baenziger, J.U., Fiete, D., Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes. Cell 22 (1980), 611–620.
-
(1980)
Cell
, vol.22
, pp. 611-620
-
-
Baenziger, J.U.1
Fiete, D.2
-
38
-
-
0023212742
-
Receptor-mediated in vitro gene transformation by a soluble DNA carrier system
-
38 Wu, G.Y., Wu, C.H., Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. 262 (1987), 4429–4432.
-
(1987)
J. Biol. Chem.
, vol.262
, pp. 4429-4432
-
-
Wu, G.Y.1
Wu, C.H.2
-
39
-
-
0023811723
-
Receptor-mediated gene delivery and expression in vivo
-
39 Wu, G.Y., Wu, C.H., Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 263 (1988), 14621–14624.
-
(1988)
J. Biol. Chem.
, vol.263
, pp. 14621-14624
-
-
Wu, G.Y.1
Wu, C.H.2
-
40
-
-
0024282306
-
Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro
-
40 Wu, G.Y., Wu, C.H., Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro. Biochemistry 27 (1988), 887–892.
-
(1988)
Biochemistry
, vol.27
, pp. 887-892
-
-
Wu, G.Y.1
Wu, C.H.2
-
41
-
-
0026952599
-
Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand
-
41 Plank, C., Zatloukal, K., Cotten, M., Mechtler, K., Wagner, E., Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand. Bioconjug. Chem. 3 (1992), 533–539.
-
(1992)
Bioconjug. Chem.
, vol.3
, pp. 533-539
-
-
Plank, C.1
Zatloukal, K.2
Cotten, M.3
Mechtler, K.4
Wagner, E.5
-
42
-
-
0028534622
-
Targeted delivery of DNA using YEE(GalNAcAH)3, a synthetic glycopeptide ligand for the asialoglycoprotein receptor
-
42 Merwin, J.R., Noell, G.S., Thomas, W.L., Chiou, H.C., DeRome, M.E., McKee, T.D., Spitalny, G.L., Findeis, M.A., Targeted delivery of DNA using YEE(GalNAcAH)3, a synthetic glycopeptide ligand for the asialoglycoprotein receptor. Bioconjug. Chem. 5 (1994), 612–620.
-
(1994)
Bioconjug. Chem.
, vol.5
, pp. 612-620
-
-
Merwin, J.R.1
Noell, G.S.2
Thomas, W.L.3
Chiou, H.C.4
DeRome, M.E.5
McKee, T.D.6
Spitalny, G.L.7
Findeis, M.A.8
-
43
-
-
0026688793
-
Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides
-
43 Wu, G.Y., Wu, C.H., Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. Biol. Chem. 267 (1992), 12436–12439.
-
(1992)
J. Biol. Chem.
, vol.267
, pp. 12436-12439
-
-
Wu, G.Y.1
Wu, C.H.2
-
44
-
-
0029401589
-
Cell-type specific and ligand specific enhancement of cellular uptake of oligodeoxynucleoside methylphosphonates covalently linked with a neoglycopeptide, YEE(ah-GalNAc)3
-
44 Hangeland, J.J., Levis, J.T., Lee, Y.C., Ts'o, P.O., Cell-type specific and ligand specific enhancement of cellular uptake of oligodeoxynucleoside methylphosphonates covalently linked with a neoglycopeptide, YEE(ah-GalNAc)3. Bioconjug. Chem. 6 (1995), 695–701.
-
(1995)
Bioconjug. Chem.
, vol.6
, pp. 695-701
-
-
Hangeland, J.J.1
Levis, J.T.2
Lee, Y.C.3
Ts'o, P.O.4
-
45
-
-
0036009641
-
Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes
-
45 Biessen, E.A., Sliedregt-Bol, K., 'T Hoen, P.A., Prince, P., Van der Bilt, E., Valentijn, A.R., Meeuwenoord, N.J., Princen, H., Bijsterbosch, M.K., Van der Marel, G.A., et al. Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes. Bioconjug. Chem. 13 (2002), 295–302.
-
(2002)
Bioconjug. Chem.
, vol.13
, pp. 295-302
-
-
Biessen, E.A.1
Sliedregt-Bol, K.2
'T Hoen, P.A.3
Prince, P.4
Van der Bilt, E.5
Valentijn, A.R.6
Meeuwenoord, N.J.7
Princen, H.8
Bijsterbosch, M.K.9
Van der Marel, G.A.10
-
46
-
-
7444229247
-
Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor
-
46 Rensen, P.C., van Leeuwen, S.H., Sliedregt, L.A., van Berkel, T.J., Biessen, E.A., Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor. J. Med. Chem. 47 (2004), 5798–5808.
-
(2004)
J. Med. Chem.
, vol.47
, pp. 5798-5808
-
-
Rensen, P.C.1
van Leeuwen, S.H.2
Sliedregt, L.A.3
van Berkel, T.J.4
Biessen, E.A.5
-
47
-
-
0033559540
-
A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2
-
47 Rohlff, C., Watson, S.A., Morris, T.M., Skelton, L., Jackman, A.L., Page, M.J., A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2. Cancer Res. 59 (1999), 1268–1272.
-
(1999)
Cancer Res.
, vol.59
, pp. 1268-1272
-
-
Rohlff, C.1
Watson, S.A.2
Morris, T.M.3
Skelton, L.4
Jackman, A.L.5
Page, M.J.6
-
48
-
-
0037087719
-
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin
-
48 Seymour, L.W., Ferry, D.R., Anderson, D., Hesslewood, S., Julyan, P.J., Poyner, R., Doran, J., Young, A.M., Burtles, S., Kerr, D.J., Cancer Research Campaign Phase I/II Clinical Trials committee. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20 (2002), 1668–1676.
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 1668-1676
-
-
Seymour, L.W.1
Ferry, D.R.2
Anderson, D.3
Hesslewood, S.4
Julyan, P.J.5
Poyner, R.6
Doran, J.7
Young, A.M.8
Burtles, S.9
Kerr, D.J.10
-
49
-
-
77955684788
-
Lactosaminated human albumin, a hepatotropic carrier of drugs
-
49 Fiume, L., Di Stefano, G., Lactosaminated human albumin, a hepatotropic carrier of drugs. Eur. J. Pharm. Sci. 40 (2010), 253–262.
-
(2010)
Eur. J. Pharm. Sci.
, vol.40
, pp. 253-262
-
-
Fiume, L.1
Di Stefano, G.2
-
50
-
-
0029935180
-
Selective sugar binding to the carbohydrate recognition domains of the rat hepatic and macrophage asialoglycoprotein receptors
-
50 Iobst, S.T., Drickamer, K., Selective sugar binding to the carbohydrate recognition domains of the rat hepatic and macrophage asialoglycoprotein receptors. J. Biol. Chem. 271 (1996), 6686–6693.
-
(1996)
J. Biol. Chem.
, vol.271
, pp. 6686-6693
-
-
Iobst, S.T.1
Drickamer, K.2
-
51
-
-
0035813160
-
Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo
-
51 Rensen, P.C., Sliedregt, L.A., Ferns, M., Kieviet, E., van Rossenberg, S.M., van Leeuwen, S.H., van Berkel, T.J., Biessen, E.A., Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J. Biol. Chem. 276 (2001), 37577–37584.
-
(2001)
J. Biol. Chem.
, vol.276
, pp. 37577-37584
-
-
Rensen, P.C.1
Sliedregt, L.A.2
Ferns, M.3
Kieviet, E.4
van Rossenberg, S.M.5
van Leeuwen, S.H.6
van Berkel, T.J.7
Biessen, E.A.8
-
52
-
-
43049125473
-
Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor
-
52 Khorev, O., Stokmaier, D., Schwardt, O., Cutting, B., Ernst, B., Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg. Med. Chem. 16 (2008), 5216–5231.
-
(2008)
Bioorg. Med. Chem.
, vol.16
, pp. 5216-5231
-
-
Khorev, O.1
Stokmaier, D.2
Schwardt, O.3
Cutting, B.4
Ernst, B.5
-
53
-
-
0019190912
-
Human hepatic lectin. Physiochemical properties and specificity
-
53 Baenziger, J.U., Maynard, Y., Human hepatic lectin. Physiochemical properties and specificity. J. Biol. Chem. 255 (1980), 4607–4613.
-
(1980)
J. Biol. Chem.
, vol.255
, pp. 4607-4613
-
-
Baenziger, J.U.1
Maynard, Y.2
-
54
-
-
0021099058
-
Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features
-
54 Lee, Y.C., Townsend, R.R., Hardy, M.R., Lönngren, J., Arnarp, J., Haraldsson, M., Lönn, H., Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features. J. Biol. Chem. 258 (1983), 199–202.
-
(1983)
J. Biol. Chem.
, vol.258
, pp. 199-202
-
-
Lee, Y.C.1
Townsend, R.R.2
Hardy, M.R.3
Lönngren, J.4
Arnarp, J.5
Haraldsson, M.6
Lönn, H.7
-
55
-
-
0028903260
-
Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor
-
55 Biessen, E.A., Beuting, D.M., Roelen, H.C., van de Marel, G.A., van Boom, J.H., van Berkel, T.J., Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor. J. Med. Chem. 38 (1995), 1538–1546.
-
(1995)
J. Med. Chem.
, vol.38
, pp. 1538-1546
-
-
Biessen, E.A.1
Beuting, D.M.2
Roelen, H.C.3
van de Marel, G.A.4
van Boom, J.H.5
van Berkel, T.J.6
-
56
-
-
84938056583
-
Asialoglycoprotein Receptor and Its Application in Liver-targeted Drug Delivery
-
56 Huang, Y.Y., Liang, Z.C., Asialoglycoprotein Receptor and Its Application in Liver-targeted Drug Delivery. Prog Biochem Biophys 42 (2015), 501–510.
-
(2015)
Prog Biochem Biophys
, vol.42
, pp. 501-510
-
-
Huang, Y.Y.1
Liang, Z.C.2
-
57
-
-
84918578407
-
Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing
-
57 Nair, J.K., Willoughby, J.L., Chan, A., Charisse, K., Alam, M.R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel'in, A.V., Milstein, S., et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136 (2014), 16958–16961.
-
(2014)
J. Am. Chem. Soc.
, vol.136
, pp. 16958-16961
-
-
Nair, J.K.1
Willoughby, J.L.2
Chan, A.3
Charisse, K.4
Alam, M.R.5
Wang, Q.6
Hoekstra, M.7
Kandasamy, P.8
Kel'in, A.V.9
Milstein, S.10
-
58
-
-
84926320054
-
Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo
-
58 Rajeev, K.G., Nair, J.K., Jayaraman, M., Charisse, K., Taneja, N., O'Shea, J., Willoughby, J.L., Yucius, K., Nguyen, T., Shulga-Morskaya, S., et al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. ChemBioChem 16 (2015), 903–908.
-
(2015)
ChemBioChem
, vol.16
, pp. 903-908
-
-
Rajeev, K.G.1
Nair, J.K.2
Jayaraman, M.3
Charisse, K.4
Taneja, N.5
O'Shea, J.6
Willoughby, J.L.7
Yucius, K.8
Nguyen, T.9
Shulga-Morskaya, S.10
-
59
-
-
85176836684
-
-
Rajeev, K.G.Zimmermann, T., Manoharan, M., Maier., M., Kuchimanchi, S., and Charisse, K. (2013). Modified RNAi agents. U.S. Patent WO2013074974.
-
59 Rajeev, K.G.Zimmermann, T., Manoharan, M., Maier., M., Kuchimanchi, S., and Charisse, K. (2013). Modified RNAi agents. U.S. Patent WO2013074974.
-
-
-
-
60
-
-
85176862519
-
-
(2016). Modified double-stranded RNA agents. U.S. Patent WO2016028649.
-
60 Maier, M., Foster, D., Milstein, S., Kuchimanchi, S., Jadhav, V.,Rajeev, K., Manoharan, M., and Parmar, R. (2016). Modified double-stranded RNA agents. U.S. Patent WO2016028649.
-
-
-
Maier, M.1
Foster, D.2
Milstein, S.3
Kuchimanchi, S.4
Jadhav, V.5
Rajeev, K.6
Manoharan, M.7
Parmar, R.8
-
61
-
-
84964582919
-
5′-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates
-
61 Parmar, R., Willoughby, J.L., Liu, J., Foster, D.J., Brigham, B., Theile, C.S., Charisse, K., Akinc, A., Guidry, E., Pei, Y., et al. 5′-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates. ChemBioChem 17 (2016), 985–989.
-
(2016)
ChemBioChem
, vol.17
, pp. 985-989
-
-
Parmar, R.1
Willoughby, J.L.2
Liu, J.3
Foster, D.J.4
Brigham, B.5
Theile, C.S.6
Charisse, K.7
Akinc, A.8
Guidry, E.9
Pei, Y.10
-
62
-
-
84964940266
-
Synergistic effect of phosphorothioate, 5′-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA
-
62 Prakash, T.P., Kinberger, G.A., Murray, H.M., Chappell, A., Riney, S., Graham, M.J., Lima, W.F., Swayze, E.E., Seth, P.P., Synergistic effect of phosphorothioate, 5′-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA. Bioorg. Med. Chem. Lett. 26 (2016), 2817–2820.
-
(2016)
Bioorg. Med. Chem. Lett.
, vol.26
, pp. 2817-2820
-
-
Prakash, T.P.1
Kinberger, G.A.2
Murray, H.M.3
Chappell, A.4
Riney, S.5
Graham, M.J.6
Lima, W.F.7
Swayze, E.E.8
Seth, P.P.9
-
63
-
-
85176868621
-
-
Alnylam. (2014). Advances in Delivery of RNAi Therapeutics with Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates.
-
63 Alnylam. (2014). Advances in Delivery of RNAi Therapeutics with Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates. http://www.alnylam.com/web/assets/Roundtable_ESC-GalNAc-Conjugates_072214.pdf.
-
-
-
-
64
-
-
84948142085
-
Evolving landscape in the management of transthyretin amyloidosis
-
64 Hawkins, P.N., Ando, Y., Dispenzeri, A., Gonzalez-Duarte, A., Adams, D., Suhr, O.B., Evolving landscape in the management of transthyretin amyloidosis. Ann. Med. 47 (2015), 625–638.
-
(2015)
Ann. Med.
, vol.47
, pp. 625-638
-
-
Hawkins, P.N.1
Ando, Y.2
Dispenzeri, A.3
Gonzalez-Duarte, A.4
Adams, D.5
Suhr, O.B.6
-
65
-
-
84962124696
-
279 Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis
-
65 Butler, J.S., Chan, A., Costelha, S., Fishman, S., Willoughby, J.L., Borland, T.D., Milstein, S., Foster, D.J., Gonçalves, P., Chen, Q., et al. 279 Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid 23 (2016), 109–118.
-
(2016)
Amyloid
, vol.23
, pp. 109-118
-
-
Butler, J.S.1
Chan, A.2
Costelha, S.3
Fishman, S.4
Willoughby, J.L.5
Borland, T.D.6
Milstein, S.7
Foster, D.J.8
Gonçalves, P.9
Chen, Q.10
-
66
-
-
84990304685
-
Pre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated With Alpha-1-Antitrypsin Deficiency
-
66 Sehgal, A., Blomenkamp, K.S., Qian, K., Simon, A., Haslett, P., Barros, S., et al. Pre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated With Alpha-1-Antitrypsin Deficiency. Gastroenterology, 148, 2015, S-975.
-
(2015)
Gastroenterology
, vol.148
, pp. S-975
-
-
Sehgal, A.1
Blomenkamp, K.S.2
Qian, K.3
Simon, A.4
Haslett, P.5
Barros, S.6
-
67
-
-
0030829919
-
Inhibition of coagulation by a phosphorothioate oligonucleotide
-
67 Henry, S.P., Novotny, W., Leeds, J., Auletta, C., Kornbrust, D.J., Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 7 (1997), 503–510.
-
(1997)
Antisense Nucleic Acid Drug Dev.
, vol.7
, pp. 503-510
-
-
Henry, S.P.1
Novotny, W.2
Leeds, J.3
Auletta, C.4
Kornbrust, D.J.5
-
68
-
-
79959624824
-
Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2
-
68 Ferdinandi, E.S., Vassilakos, A., Lee, Y., Lightfoot, J., Fitsialos, D., Wright, J.A., Young, A.H., Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2. Cancer Chemother. Pharmacol. 68 (2011), 193–205.
-
(2011)
Cancer Chemother. Pharmacol.
, vol.68
, pp. 193-205
-
-
Ferdinandi, E.S.1
Vassilakos, A.2
Lee, Y.3
Lightfoot, J.4
Fitsialos, D.5
Wright, J.A.6
Young, A.H.7
-
69
-
-
84987630012
-
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic
-
69 Moreno, P.M., Pêgo, A.P., Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem., 2, 2014, 87.
-
(2014)
Front Chem.
, vol.2
, pp. 87
-
-
Moreno, P.M.1
Pêgo, A.P.2
-
70
-
-
85176862829
-
-
Alnylam. (2015). Alnylam R&D Day.
-
70 Alnylam. (2015). Alnylam R&D Day. http://files.shareholder.com/downloads/ABEA-430HSO/1862527561x0x865960/B08F6EC1-4FF6-48AD-A2E3-8CB626DE3B5D/RD_Day_2015_Full_Day_FINALnapdf.
-
-
-
-
71
-
-
84937764228
-
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
-
71 Sehgal, A., Barros, S., Ivanciu, L., Cooley, B., Qin, J., Racie, T., Hettinger, J., Carioto, M., Jiang, Y., Brodsky, J., et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat. Med. 21 (2015), 492–497.
-
(2015)
Nat. Med.
, vol.21
, pp. 492-497
-
-
Sehgal, A.1
Barros, S.2
Ivanciu, L.3
Cooley, B.4
Qin, J.5
Racie, T.6
Hettinger, J.7
Carioto, M.8
Jiang, Y.9
Brodsky, J.10
-
72
-
-
84985041005
-
Emerging drugs for the treatment of hemophilia A and B
-
72 Morfini, M., Zanon, E., Emerging drugs for the treatment of hemophilia A and B. Expert Opin. Emerg. Drugs 21 (2016), 301–313.
-
(2016)
Expert Opin. Emerg. Drugs
, vol.21
, pp. 301-313
-
-
Morfini, M.1
Zanon, E.2
-
73
-
-
85015675094
-
NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY
-
73 Strat, A.L., Ghiciuc, C.M., Lupuşoru, C.E., Mitu, F., NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY. Rev. Med. Chir. Soc. Med. Nat. Iasi 120 (2016), 228–232.
-
(2016)
Rev. Med. Chir. Soc. Med. Nat. Iasi
, vol.120
, pp. 228-232
-
-
Strat, A.L.1
Ghiciuc, C.M.2
Lupuşoru, C.E.3
Mitu, F.4
-
74
-
-
84960330442
-
Novel therapies for severe dyslipidemia originating from human genetics
-
74 Gaudet, D., Novel therapies for severe dyslipidemia originating from human genetics. Curr. Opin. Lipidol. 27 (2016), 112–124.
-
(2016)
Curr. Opin. Lipidol.
, vol.27
, pp. 112-124
-
-
Gaudet, D.1
-
75
-
-
84991827712
-
A subcutaneously administered investigational RNAi therapeutic (ALN-CC5) targeting complement C5 for treatment of PNH and complement-mediated diseases: interim Phase 1 study results
-
75 Hill, A., Taubel, J., Bush, J., Borodovsky, A., Kawahata, N., McLean, H., Powell, C., Chaturvedi, P., Warner, G., Garg, P., et al. A subcutaneously administered investigational RNAi therapeutic (ALN-CC5) targeting complement C5 for treatment of PNH and complement-mediated diseases: interim Phase 1 study results. Blood, 126, 2015, 2413.
-
(2015)
Blood
, vol.126
, pp. 2413
-
-
Hill, A.1
Taubel, J.2
Bush, J.3
Borodovsky, A.4
Kawahata, N.5
McLean, H.6
Powell, C.7
Chaturvedi, P.8
Warner, G.9
Garg, P.10
-
76
-
-
85016299478
-
An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria
-
ASN.2016030338
-
76 Liebow, A., Li, X., Racie, T., Hettinger, J., Bettencourt, B.R., Najafian, N., Haslett, P., Fitzgerald, K., Holmes, R.P., Erbe, D., et al. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J. Am. Soc. Nephrol., 2016 ASN.2016030338.
-
(2016)
J. Am. Soc. Nephrol.
-
-
Liebow, A.1
Li, X.2
Racie, T.3
Hettinger, J.4
Bettencourt, B.R.5
Najafian, N.6
Haslett, P.7
Fitzgerald, K.8
Holmes, R.P.9
Erbe, D.10
-
77
-
-
84982908689
-
Stones: A novel RNAi therapy for PH1
-
77 Carney, E.F., Stones: A novel RNAi therapy for PH1. Nat. Rev. Nephrol., 12, 2016, 508.
-
(2016)
Nat. Rev. Nephrol.
, vol.12
, pp. 508
-
-
Carney, E.F.1
-
78
-
-
84991579783
-
Aiming for cure in HBV and HDV infection
-
78 Petersen, J., Thompson, A.J., Levrero, M., Aiming for cure in HBV and HDV infection. J. Hepatol. 65 (2016), 835–848.
-
(2016)
J. Hepatol.
, vol.65
, pp. 835-848
-
-
Petersen, J.1
Thompson, A.J.2
Levrero, M.3
-
79
-
-
84938521049
-
Progress and prospects of anti-HBV gene therapy development
-
79 Maepa, M.B., Roelofse, I., Ely, A., Arbuthnot, P., Progress and prospects of anti-HBV gene therapy development. Int. J. Mol. Sci. 16 (2015), 17589–17610.
-
(2015)
Int. J. Mol. Sci.
, vol.16
, pp. 17589-17610
-
-
Maepa, M.B.1
Roelofse, I.2
Ely, A.3
Arbuthnot, P.4
-
80
-
-
84901660512
-
RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice
-
80 Yasuda, M., Gan, L., Chen, B., Kadirvel, S., Yu, C., Phillips, J.D., New, M.I., Liebow, A., Fitzgerald, K., Querbes, W., Desnick, R.J., RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proc. Natl. Acad. Sci. USA 111 (2014), 7777–7782.
-
(2014)
Proc. Natl. Acad. Sci. USA
, vol.111
, pp. 7777-7782
-
-
Yasuda, M.1
Gan, L.2
Chen, B.3
Kadirvel, S.4
Yu, C.5
Phillips, J.D.6
New, M.I.7
Liebow, A.8
Fitzgerald, K.9
Querbes, W.10
Desnick, R.J.11
-
81
-
-
84961202707
-
Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification
-
81 Chan, A., Liebow, A., Yasuda, M., Gan, L., Racie, T., Maier, M., Kuchimanchi, S., Foster, D., Milstein, S., Charisse, K., et al. Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification. Mol. Ther. Nucleic Acids, 4, 2015, e263.
-
(2015)
Mol. Ther. Nucleic Acids
, vol.4
, pp. e263
-
-
Chan, A.1
Liebow, A.2
Yasuda, M.3
Gan, L.4
Racie, T.5
Maier, M.6
Kuchimanchi, S.7
Foster, D.8
Milstein, S.9
Charisse, K.10
-
82
-
-
84929574453
-
siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes
-
82 Matsuda, S., Keiser, K., Nair, J.K., Charisse, K., Manoharan, R.M., Kretschmer, P., Peng, C.G., V Kel'in, A., Kandasamy, P., Willoughby, J.L., et al. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol. 10 (2015), 1181–1187.
-
(2015)
ACS Chem. Biol.
, vol.10
, pp. 1181-1187
-
-
Matsuda, S.1
Keiser, K.2
Nair, J.K.3
Charisse, K.4
Manoharan, R.M.5
Kretschmer, P.6
Peng, C.G.7
V Kel'in, A.8
Kandasamy, P.9
Willoughby, J.L.10
-
83
-
-
34548735210
-
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
-
83 Rozema, D.B., Lewis, D.L., Wakefield, D.H., Wong, S.C., Klein, J.J., Roesch, P.L., Bertin, S.L., Reppen, T.W., Chu, Q., Blokhin, A.V., et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. USA 104 (2007), 12982–12987.
-
(2007)
Proc. Natl. Acad. Sci. USA
, vol.104
, pp. 12982-12987
-
-
Rozema, D.B.1
Lewis, D.L.2
Wakefield, D.H.3
Wong, S.C.4
Klein, J.J.5
Roesch, P.L.6
Bertin, S.L.7
Reppen, T.W.8
Chu, Q.9
Blokhin, A.V.10
-
84
-
-
84870570270
-
Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo
-
84 Wong, S.C., Klein, J.J., Hamilton, H.L., Chu, Q., Frey, C.L., Trubetskoy, V.S., Hegge, J., Wakefield, D., Rozema, D.B., Lewis, D.L., Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther. 22 (2012), 380–390.
-
(2012)
Nucleic Acid Ther.
, vol.22
, pp. 380-390
-
-
Wong, S.C.1
Klein, J.J.2
Hamilton, H.L.3
Chu, Q.4
Frey, C.L.5
Trubetskoy, V.S.6
Hegge, J.7
Wakefield, D.8
Rozema, D.B.9
Lewis, D.L.10
-
85
-
-
84955349803
-
Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes
-
85 Sebestyén, M.G., Wong, S.C., Trubetskoy, V., Lewis, D.L., Wooddell, C.I., Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes. Methods Mol. Biol. 1218 (2015), 163–186.
-
(2015)
Methods Mol. Biol.
, vol.1218
, pp. 163-186
-
-
Sebestyén, M.G.1
Wong, S.C.2
Trubetskoy, V.3
Lewis, D.L.4
Wooddell, C.I.5
-
86
-
-
84928379371
-
Protease-triggered siRNA delivery vehicles
-
86 Rozema, D.B., Blokhin, A.V., Wakefield, D.H., Benson, J.D., Carlson, J.C., Klein, J.J., Almeida, L.J., Nicholas, A.L., Hamilton, H.L., Chu, Q., et al. Protease-triggered siRNA delivery vehicles. J. Control. Release 209 (2015), 57–66.
-
(2015)
J. Control. Release
, vol.209
, pp. 57-66
-
-
Rozema, D.B.1
Blokhin, A.V.2
Wakefield, D.H.3
Benson, J.D.4
Carlson, J.C.5
Klein, J.J.6
Almeida, L.J.7
Nicholas, A.L.8
Hamilton, H.L.9
Chu, Q.10
-
87
-
-
84886261520
-
Delivery materials for siRNA therapeutics
-
87 Kanasty, R., Dorkin, J.R., Vegas, A., Anderson, D., Delivery materials for siRNA therapeutics. Nat. Mater. 12 (2013), 967–977.
-
(2013)
Nat. Mater.
, vol.12
, pp. 967-977
-
-
Kanasty, R.1
Dorkin, J.R.2
Vegas, A.3
Anderson, D.4
-
88
-
-
79957460418
-
Endosomal escape pathways for delivery of biologicals
-
88 Varkouhi, A.K., Scholte, M., Storm, G., Haisma, H.J., Endosomal escape pathways for delivery of biologicals. J. Control. Release 151 (2011), 220–228.
-
(2011)
J. Control. Release
, vol.151
, pp. 220-228
-
-
Varkouhi, A.K.1
Scholte, M.2
Storm, G.3
Haisma, H.J.4
-
89
-
-
84968743695
-
ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B
-
89 Yuen, M.F., Chan, H.L.Y., Liu, S.H.K., Given, B., Schluep, T., Hamilton, J., Lai, C.L., Locarnini, S., Lau, J.Y., Ferrari, C., Gish, R.G., ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B. Hepatology, 62, 2015, 1385A.
-
(2015)
Hepatology
, vol.62
, pp. 1385A
-
-
Yuen, M.F.1
Chan, H.L.Y.2
Liu, S.H.K.3
Given, B.4
Schluep, T.5
Hamilton, J.6
Lai, C.L.7
Locarnini, S.8
Lau, J.Y.9
Ferrari, C.10
Gish, R.G.11
-
90
-
-
85176865832
-
-
Arrowhead. (2016). Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521.
-
90 Arrowhead. (2016). Arrowhead Pharmaceuticals Doses First Patient with Hepatitis B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521. http://files.shareholder.com/downloads/AMDA-2OTJP1/1862504966x0x907254/5730467A-2DC8-4079-97B0-195D1A96B95A/ARWR_News_2016_9_7_General_Releases.pdf.
-
-
-
-
91
-
-
85176851067
-
-
Dicerna. (2016). Welcome to Investor Day.
-
91 Dicerna. (2016). Welcome to Investor Day. http://files.shareholder.com/downloads/AMDA-2IH3D0/3375799178x0x898098/D565497C-DCC6-40C5-91C7-60C010D9A346/DicernaInvestorDayJune292016.pdf.
-
-
-
-
92
-
-
85006071413
-
A single subcutaneous dose of 2 mg/kg or 4 mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against miR-122, results in significant viral load reductions in chronic hepatitis C patients
-
92 Van der Ree, M., de Vree, M.L., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., Molenkamp, R., Schinkel, J., Hadi, S., Harbers, M., et al. A single subcutaneous dose of 2 mg/kg or 4 mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against miR-122, results in significant viral load reductions in chronic hepatitis C patients. J. Hepatol., 62, 2015, S261.
-
(2015)
J. Hepatol.
, vol.62
, pp. S261
-
-
Van der Ree, M.1
de Vree, M.L.2
Stelma, F.3
Willemse, S.4
van der Valk, M.5
Rietdijk, S.6
Molenkamp, R.7
Schinkel, J.8
Hadi, S.9
Harbers, M.10
-
93
-
-
85010850526
-
MicroRNAs in Metabolism
-
93 Vienberg, S., Geiger, J., Madsen, S., Dalgaard, L.T., MicroRNAs in Metabolism. Acta Physiol. (Oxf.), 2016.
-
(2016)
Acta Physiol. (Oxf.)
-
-
Vienberg, S.1
Geiger, J.2
Madsen, S.3
Dalgaard, L.T.4
-
94
-
-
84905584822
-
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
-
94 Prakash, T.P., Graham, M.J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H.F., et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42 (2014), 8796–8807.
-
(2014)
Nucleic Acids Res.
, vol.42
, pp. 8796-8807
-
-
Prakash, T.P.1
Graham, M.J.2
Yu, J.3
Carty, R.4
Low, A.5
Chappell, A.6
Schmidt, K.7
Zhao, C.8
Aghajan, M.9
Murray, H.F.10
-
95
-
-
84864199342
-
Structure and nuclease resistance of 2′,4′-constrained 2′-O-methoxyethyl (cMOE) and 2′-O-ethyl (cEt) modified DNAs
-
95 Pallan, P.S., Allerson, C.R., Berdeja, A., Seth, P.P., Swayze, E.E., Prakash, T.P., Egli, M., Structure and nuclease resistance of 2′,4′-constrained 2′-O-methoxyethyl (cMOE) and 2′-O-ethyl (cEt) modified DNAs. Chem. Commun. (Camb.) 48 (2012), 8195–8197.
-
(2012)
Chem. Commun. (Camb.)
, vol.48
, pp. 8195-8197
-
-
Pallan, P.S.1
Allerson, C.R.2
Berdeja, A.3
Seth, P.P.4
Swayze, E.E.5
Prakash, T.P.6
Egli, M.7
-
96
-
-
84962171168
-
Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes
-
96 Prakash, T.P., Yu, J., Migawa, M.T., Kinberger, G.A., Wan, W.B., Østergaard, M.E., Carty, R.L., Vasquez, G., Low, A., Chappell, A., et al. Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes. J. Med. Chem. 59 (2016), 2718–2733.
-
(2016)
J. Med. Chem.
, vol.59
, pp. 2718-2733
-
-
Prakash, T.P.1
Yu, J.2
Migawa, M.T.3
Kinberger, G.A.4
Wan, W.B.5
Østergaard, M.E.6
Carty, R.L.7
Vasquez, G.8
Low, A.9
Chappell, A.10
-
97
-
-
84965106860
-
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
-
97 Yu, R.Z., Graham, M.J., Post, N., Riney, S., Zanardi, T., Hall, S., Burkey, J., Shemesh, C.S., Prakash, T.P., Seth, P.P., et al. Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice. Mol. Ther. Nucleic Acids, 5, 2016, e317.
-
(2016)
Mol. Ther. Nucleic Acids
, vol.5
, pp. e317
-
-
Yu, R.Z.1
Graham, M.J.2
Post, N.3
Riney, S.4
Zanardi, T.5
Hall, S.6
Burkey, J.7
Shemesh, C.S.8
Prakash, T.P.9
Seth, P.P.10
-
98
-
-
84985000693
-
Development of Antisense Drugs for Dyslipidemia
-
98 Yamamoto, T., Wada, F., Harada-Shiba, M., Development of Antisense Drugs for Dyslipidemia. J. Atheroscler. Thromb. 23 (2016), 1011–1025.
-
(2016)
J. Atheroscler. Thromb.
, vol.23
, pp. 1011-1025
-
-
Yamamoto, T.1
Wada, F.2
Harada-Shiba, M.3
-
99
-
-
85015678091
-
Potent antisense oligonucleotides to Apo(a) normalize plasma LP(a) levels in the majority of people with elevated LP(a): results of ISIS-APO(a)Rx Phase 2 and ISIS-APO(a)-LRx Phase 1 trials
-
99 Viney, N., Marcovina, S., Xia, S.T., Geary, R., Witztum, J., Tsimikas, S., Potent antisense oligonucleotides to Apo(a) normalize plasma LP(a) levels in the majority of people with elevated LP(a): results of ISIS-APO(a)Rx Phase 2 and ISIS-APO(a)-LRx Phase 1 trials. J. Am. Coll. Cardiol., 67, 2016, 2081.
-
(2016)
J. Am. Coll. Cardiol.
, vol.67
, pp. 2081
-
-
Viney, N.1
Marcovina, S.2
Xia, S.T.3
Geary, R.4
Witztum, J.5
Tsimikas, S.6
-
100
-
-
85015610805
-
Future Therapy for HBV: Role of Cell Cycle Inhibitors
-
100 Brahmania, M., Janssen, H.L.A., Future Therapy for HBV: Role of Cell Cycle Inhibitors. Curr. Hepatol. Rep., 15, 2016, 245.
-
(2016)
Curr. Hepatol. Rep.
, vol.15
, pp. 245
-
-
Brahmania, M.1
Janssen, H.L.A.2
-
101
-
-
84992193857
-
Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities
-
101 Boucle, S., Bassit, L., Ehteshami, M., Schinazi, R.F., Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. Clin. Liver Dis. 20 (2016), 737–749.
-
(2016)
Clin. Liver Dis.
, vol.20
, pp. 737-749
-
-
Boucle, S.1
Bassit, L.2
Ehteshami, M.3
Schinazi, R.F.4
-
102
-
-
84979297862
-
Current and future medical treatments for patients with acromegaly
-
102 Maffezzoni, F., Formenti, A.M., Mazziotti, G., Frara, S., Giustina, A., Current and future medical treatments for patients with acromegaly. Expert Opin. Pharmacother. 17 (2016), 1631–1642.
-
(2016)
Expert Opin. Pharmacother.
, vol.17
, pp. 1631-1642
-
-
Maffezzoni, F.1
Formenti, A.M.2
Mazziotti, G.3
Frara, S.4
Giustina, A.5
-
103
-
-
84991823729
-
2017 Clinical trials update in new treatments of β-thalassemia
-
103 Makis, A., Hatzimichael, E., Papassotiriou, I., Voskaridou, E., 2017 Clinical trials update in new treatments of β-thalassemia. Am. J. Hematol. 91 (2016), 1135–1145.
-
(2016)
Am. J. Hematol.
, vol.91
, pp. 1135-1145
-
-
Makis, A.1
Hatzimichael, E.2
Papassotiriou, I.3
Voskaridou, E.4
-
104
-
-
84944930132
-
Solid-phase synthesis of 5′-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry
-
104 Prakash, T.P., Brad Wan, W., Low, A., Yu, J., Chappell, A.E., Gaus, H., Kinberger, G.A., Østergaard, M.E., Migawa, M.T., Swayze, E.E., Seth, P.P., Solid-phase synthesis of 5′-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry. Bioorg. Med. Chem. Lett. 25 (2015), 4127–4130.
-
(2015)
Bioorg. Med. Chem. Lett.
, vol.25
, pp. 4127-4130
-
-
Prakash, T.P.1
Brad Wan, W.2
Low, A.3
Yu, J.4
Chappell, A.E.5
Gaus, H.6
Kinberger, G.A.7
Østergaard, M.E.8
Migawa, M.T.9
Swayze, E.E.10
Seth, P.P.11
-
105
-
-
84939800605
-
Efficient synthesis and biological evaluation of 5′-GalNAc conjugated antisense oligonucleotides
-
105 Østergaard, M.E., Yu, J., Kinberger, G.A., Wan, W.B., Migawa, M.T., Vasquez, G., Schmidt, K., Gaus, H.J., Murray, H.M., Low, A., et al. Efficient synthesis and biological evaluation of 5′-GalNAc conjugated antisense oligonucleotides. Bioconjug. Chem. 26 (2015), 1451–1455.
-
(2015)
Bioconjug. Chem.
, vol.26
, pp. 1451-1455
-
-
Østergaard, M.E.1
Yu, J.2
Kinberger, G.A.3
Wan, W.B.4
Migawa, M.T.5
Vasquez, G.6
Schmidt, K.7
Gaus, H.J.8
Murray, H.M.9
Low, A.10
-
106
-
-
84961782173
-
A convenient synthesis of 5′-triantennary N-acetyl-galactosamine clusters based on nitromethanetrispropionic acid
-
106 Migawa, M.T., Prakash, T.P., Vasquez, G., Wan, W.B., Yu, J., Kinberger, G.A., Østergaard, M.E., Swayze, E.E., Seth, P.P., A convenient synthesis of 5′-triantennary N-acetyl-galactosamine clusters based on nitromethanetrispropionic acid. Bioorg. Med. Chem. Lett. 26 (2016), 2194–2197.
-
(2016)
Bioorg. Med. Chem. Lett.
, vol.26
, pp. 2194-2197
-
-
Migawa, M.T.1
Prakash, T.P.2
Vasquez, G.3
Wan, W.B.4
Yu, J.5
Kinberger, G.A.6
Østergaard, M.E.7
Swayze, E.E.8
Seth, P.P.9
-
107
-
-
84971665279
-
Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes
-
107 Kinberger, G.A., Prakash, T.P., Yu, J., Vasquez, G., Low, A., Chappell, A., Schmidt, K., Murray, H.M., Gaus, H., Swayze, E.E., Seth, P.P., Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes. Bioorg. Med. Chem. Lett. 26 (2016), 3690–3693.
-
(2016)
Bioorg. Med. Chem. Lett.
, vol.26
, pp. 3690-3693
-
-
Kinberger, G.A.1
Prakash, T.P.2
Yu, J.3
Vasquez, G.4
Low, A.5
Chappell, A.6
Schmidt, K.7
Murray, H.M.8
Gaus, H.9
Swayze, E.E.10
Seth, P.P.11
-
108
-
-
84949782714
-
Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides
-
108 Yamamoto, T., Sawamura, M., Wada, F., Harada-Shiba, M., Obika, S., Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides. Bioorg. Med. Chem. 24 (2016), 26–32.
-
(2016)
Bioorg. Med. Chem.
, vol.24
, pp. 26-32
-
-
Yamamoto, T.1
Sawamura, M.2
Wada, F.3
Harada-Shiba, M.4
Obika, S.5
-
109
-
-
85015179223
-
Elucidation of the biotransformation pathways of a Galnac3-conjugated antisense oligonucleotide in rats and monkeys
-
109 Shemesh, C.S., Yu, R.Z., Gaus, H.J., Greenlee, S., Post, N., Schmidt, K., Migawa, M.T., Seth, P.P., Zanardi, T.A., Prakash, T.P., et al. Elucidation of the biotransformation pathways of a Galnac3-conjugated antisense oligonucleotide in rats and monkeys. Mol. Ther. Nucleic Acids, 5, 2016, e319.
-
(2016)
Mol. Ther. Nucleic Acids
, vol.5
, pp. e319
-
-
Shemesh, C.S.1
Yu, R.Z.2
Gaus, H.J.3
Greenlee, S.4
Post, N.5
Schmidt, K.6
Migawa, M.T.7
Seth, P.P.8
Zanardi, T.A.9
Prakash, T.P.10
-
110
-
-
85176828553
-
-
Alnylam. (2015). Next generation LDL-C management with ALN-PCSsc, an investigational PCSK9 synthesis inhibitor.
-
110 Alnylam. (2015). Next generation LDL-C management with ALN-PCSsc, an investigational PCSK9 synthesis inhibitor. http://www.themedicinescompany.com/sites/default/files/pdf/ALNY-MDCO_PCSsc_AnalystCallSlides_30Aug2015.pdf.
-
-
-
-
111
-
-
85176872573
-
-
Alnylam. (2016). 2016 RNAi Roundtable: Fitusiran for the Treatment of Hemophilia and Rare Bleeding Disorders.
-
111 Alnylam. (2016). 2016 RNAi Roundtable: Fitusiran for the Treatment of Hemophilia and Rare Bleeding Disorders. http://files.shareholder.com/downloads/ABEA-430HSO/3338525009x0x905556/3A9C92BE-BD18-49E8-A730-E481B07D4264/Fitusiran_Roundtable_102216.pdf.
-
-
-
-
112
-
-
85176832531
-
-
Alnylam. (2016). 2016 RNAi Roundtable: ALN-CC5 for the Treatment of Complement-Mediated Diseases.
-
112 Alnylam. (2016). 2016 RNAi Roundtable: ALN-CC5 for the Treatment of Complement-Mediated Diseases. http://files.shareholder.com/downloads/ABEA-430HSO/3338525009x0x906527/4976772E-32FD-4A18-9D57-34BECB083692/ALN-CC5_Roundtable_FINAL2_083116.pdf.
-
-
-
-
113
-
-
85176872878
-
-
Alnylam. (2016). 2016 RNAi Roundtable: ALN-GO1 for the treatment of primary hyperoxaluria type 1 (PH1).
-
113 Alnylam. (2016). 2016 RNAi Roundtable: ALN-GO1 for the treatment of primary hyperoxaluria type 1 (PH1). http://files.shareholder.com/downloads/ABEA-430HSO/3338525009x0x909656/3EAC5FE3-E62C-4BC1-B95E-01084BB7288F/GO1_Roundtable_Slides_092716_Final2.pdf.
-
-
-
-
114
-
-
85176857192
-
-
Alnylam. (2016). 2016 RNAi Roundtable: ALN-HBV for the treatment of hepatitis B virus (HBV) infection.
-
114 Alnylam. (2016). 2016 RNAi Roundtable: ALN-HBV for the treatment of hepatitis B virus (HBV) infection. http://files.shareholder.com/downloads/ABEA-430HSO/3338525009x0x911299/25B3A016-2BCC-4AC3-B494-5A35E2FE5F9D/ALN-HBV_Roundtable_Slides.FINAL.v3.pdf.
-
-
-
-
115
-
-
85176826051
-
-
Alnylam. (2016). 2016 RNAi Roundtable: ALN-AS1 for the treatment of acute hepatic porphyrias.
-
115 Alnylam. (2016). 2016 RNAi Roundtable: ALN-AS1 for the treatment of acute hepatic porphyrias. http://files.shareholder.com/downloads/ABEA-430HSO/3338525009x0x907951/C29D1F9A-55A8-49B8-A3F6-7443191C759B/ALN-AS1_Roundtable_FINAL_091316.pdf.
-
-
-
-
116
-
-
85176821863
-
-
Alnylam. (2015). Enhanced Pharmacologic Activity and Durability Demonstrated with an ESC GalNAc-siRNA Targeting Transthyretin.
-
116 Alnylam. (2015). Enhanced Pharmacologic Activity and Durability Demonstrated with an ESC GalNAc-siRNA Targeting Transthyretin. http://www.alnylam.com/web/assets/ALN-TTRsc02_OTS_101415.pdf.
-
-
-
-
117
-
-
84861092456
-
First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice
-
117 Pol, S., Lampertico, P., First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J. Viral Hepat. 19 (2012), 377–386.
-
(2012)
J. Viral Hepat.
, vol.19
, pp. 377-386
-
-
Pol, S.1
Lampertico, P.2
-
118
-
-
18344369543
-
MicroRNA biogenesis: coordinated cropping and dicing
-
118 Kim, V.N., MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6 (2005), 376–385.
-
(2005)
Nat. Rev. Mol. Cell Biol.
, vol.6
, pp. 376-385
-
-
Kim, V.N.1
-
119
-
-
33845755467
-
Illuminating the silence: understanding the structure and function of small RNAs
-
119 Rana, T.M., Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 8 (2007), 23–36.
-
(2007)
Nat. Rev. Mol. Cell Biol.
, vol.8
, pp. 23-36
-
-
Rana, T.M.1
-
120
-
-
77951168054
-
Breaking down the barriers: siRNA delivery and endosome escape
-
120 Dominska, M., Dykxhoorn, D.M., Breaking down the barriers: siRNA delivery and endosome escape. J. Cell Sci. 123 (2010), 1183–1189.
-
(2010)
J. Cell Sci.
, vol.123
, pp. 1183-1189
-
-
Dominska, M.1
Dykxhoorn, D.M.2
-
121
-
-
84954099191
-
RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
-
121 Bobbin, M.L., Rossi, J.J., RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?. Annu. Rev. Pharmacol. Toxicol. 56 (2016), 103–122.
-
(2016)
Annu. Rev. Pharmacol. Toxicol.
, vol.56
, pp. 103-122
-
-
Bobbin, M.L.1
Rossi, J.J.2
-
122
-
-
84903792862
-
Anti-miRs competitively inhibit microRNAs in Argonaute complexes
-
122 Hogan, D.J., Vincent, T.M., Fish, S., Marcusson, E.G., Bhat, B., Chau, B.N., Zisoulis, D.G., Anti-miRs competitively inhibit microRNAs in Argonaute complexes. PLoS ONE, 9, 2014, e100951.
-
(2014)
PLoS ONE
, vol.9
, pp. e100951
-
-
Hogan, D.J.1
Vincent, T.M.2
Fish, S.3
Marcusson, E.G.4
Bhat, B.5
Chau, B.N.6
Zisoulis, D.G.7
-
123
-
-
84856431819
-
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
-
123 Kole, R., Krainer, A.R., Altman, S., RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11 (2012), 125–140.
-
(2012)
Nat. Rev. Drug Discov.
, vol.11
, pp. 125-140
-
-
Kole, R.1
Krainer, A.R.2
Altman, S.3
|